跳至主要内容
临床试验/NCT00095914
NCT00095914已完成1 期

Randomized, Crossover, Pharmacokinetic Study Of Paclitaxel (Taxol) And ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle Paclitaxel) In Patients With Advanced Solid Tumors

National Institutes of Health Clinical Center (CC)2 个研究点 分布在 1 个国家开始时间: 2004年9月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
试验地点
2

研究概览

简要总结

RATIONALE: Drugs used in chemotherapy, such as paclitaxel and ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining paclitaxel with ABI-007 may kill more tumor cells.

PURPOSE: Randomized phase I trial to study the effectiveness of combining paclitaxel with ABI-007 in treating patients who have locally advanced or metastatic solid tumors.

详细描述

OBJECTIVES:

Primary

  • Determine whether a change in the formulation alters the pharmacokinetic profile of paclitaxel in the plasma of patients with incurable locally advanced or metastatic solid tumors treated with ABI-007 and paclitaxel.

Secondary

  • Correlate pharmacokinetic data of this regimen with decrease in the neutrophil count at nadir in these patients.
  • Determine the intra- and interindividual pharmacokinetic variability of ABI-007 in these patients.
  • Determine protein binding of paclitaxel via measurement of α-1-acid glycoprotein and serum albumin levels in patients treated with this regimen.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

研究点 (2)

Loading locations...

相似试验

Paclitaxel and ABI-007 in Treating Patients With... | 临床试验